Our aim was to analyze the virological response to a combined antiretroviral therapy started after Maraviroc Clinical Test (MCT) in naïve HIV-infected patients. Forty-one patients were exposed to MCT, based on an 8-day MVC monotherapy. If undetectability or a viral load reduction >1 log10 HIV-RNA copies/ml was achieved, a MVC-containing cART was prescribed. Forty patients showed a positive MCT; undetectability after 48weeks on cART was achieved in 34/41 (82.9%) patients. The result of MCT was compared with a genotypic tropism method and with Trofile®, showing 10.7% and 18.75% discordance rates, respectively. MCT is a reliable tool to decide CCR5-antagonists prescription, also in the naïve scenario where most patients show a virological response to MVC independently the tropism result reported by genotypic or phenotypic methods.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.antiviral.2015.06.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatments for Long COVID autonomic dysfunction: a scoping review.
Clin Auton Res
December 2024
ECRI-Penn Evidence-Based Practice Center, 5200 Butler Pike, Plymouth Meeting, PA, 19462, USA.
Purpose: For Long COVID autonomic dysfunction, we have summarized published evidence on treatment effectiveness, clinical practice guidelines, and unpublished/ongoing studies.
Methods: We first interviewed 11 stakeholders (clinicians, clinician/researchers, payors, patient advocates) to gain clinical insights and identify key areas of focus. We searched Embase, CINAHL, Medline, PsycINFO, and PubMed databases for relevant English-language articles published between 1 January 2020 and 30 April 2024.
Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis.
Braz J Infect Dis
December 2024
Hospital de Clínicas de Porto Alegre, Departamento de Doenças Infecciosas, Porto Alegre, RS, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil. Electronic address:
Background: Antiretroviral drug simplification is a strategy to reduce drug exposure and improve treatment adherence. Nowadays, dolutegravir plus lamivudine is the most preferred regimen, which might lead in the future with problems related to drug resistance or drug intolerance. This meta-analysis aimed to assess the safety of HAART simplification without integrase inhibitors.
View Article and Find Full Text PDFThe chemokine receptor type 5 inhibitor maraviroc alleviates sepsis-associated liver injury by regulating MAPK/NF-κB signaling.
Naunyn Schmiedebergs Arch Pharmacol
October 2024
Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225009, China.
Article Synopsis
- - Sepsis-related organ damage, particularly sepsis-associated liver injury (SALI), is a significant challenge in intensive care, often resulting in poor patient outcomes due to complex physiological issues.
- - The study investigates the effectiveness of maraviroc (MVC), a CCR5 inhibitor, in treating SALI using a cecal ligation and puncture (CLP) model, where MVC was injected post-surgery, leading to significant improvements in liver injury.
- - Results indicate that MVC reduces liver inflammation and cell apoptosis by inhibiting specific inflammatory signaling pathways (NF-κB and MAPK), with these effects reversed when a JNK agonist was used, highlighting MVC's potential in managing SALI.
Blockade of CCR5 T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody.
Adv Sci (Weinh)
November 2024
Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, P. R. China.
Article Synopsis
- The study investigates the bispecific antibody YM101, which shows better results than anti-PD-L1 alone in fighting tumors, but still fails to completely eliminate tumors in mice, indicating other immunosuppressive factors in the tumor microenvironment (TME).
- Researchers used single-cell RNA sequencing (scRNA-seq) to analyze changes in the TME caused by YM101, discovering increased immune cell populations boosting antitumor activity, yet also finding immunosuppressive CCR5 T cells.
- To improve YM101's effectiveness, the researchers combined it with Maraviroc, a CCR5 antagonist, which reduced the harmful CCR5 T cells and enhanced the overall antitumor immune response, suggesting that targeting CCR5 could
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
J Acquir Immune Defic Syndr
October 2024
Department of Medical Sciences, Unit of Infectious Diseases, University of Turin, Turin, Italy.
Article Synopsis
- The study investigated the impact of switching to a less neurotoxic antiretroviral therapy (ARV) on neurocognitive performance in people living with HIV who have cognitive impairments.
- Participants were randomly assigned to either continue their current treatment or switch to a less harmful ARV regimen (MARAND-X) for 24 weeks, with results measured using various cognitive tests and electroencephalography.
- While the overall neurocognitive scores improved modestly, significant improvements were only seen in specific memory functions for those in the MARAND-X group with better CNS penetration, indicating that the effectiveness of ARVs in the central nervous system may influence cognitive health.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!